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ABSTRACT
Introduction Bronchiectasis is characterised by 
excessive neutrophilic inflammation. Lipid mediators such 
as prostaglandins and leukotrienes have crucial roles in 
the inflammatory response. Further characterisation of 
these lipids and understanding the interplay of anti- 
inflammatory and proinflammatory lipid mediators could 
lead to the development of novel anti- inflammatory 
therapies for bronchiectasis.
Aim The aim of our study was to characterise the 
lipids obtained from serum and airways in patients with 
bronchiectasis in the stable state.
Methods Six healthy volunteers, 10 patients with 
mild bronchiectasis, 15 with moderate bronchiectasis 
and 9 with severe bronchiectasis were recruited. All 
participants had 60 mL of blood taken and underwent a 
bronchoscopy while in the stable state. Lipidomics was 
done on serum and bronchoalveolar lavage fluid (BALF).
Results In the stable state, in serum there were 
significantly higher levels of prostaglandin E2 (PGE2), 
15- hydroxyeicosatetranoic acid (15- HETE) and 
leukotriene B4 (LTB4) in patients with moderate–severe 
disease compared with healthy volunteers. There was 
a significantly lower level of lipoxin A4 (LXA4) in severe 
bronchiectasis.
In BALF, there were significantly higher levels of PGE2, 
5- HETE, 15- HETE, 9- hydroxyoctadecadienoic acid and 
LTB4 in moderate–severe patients compared with healthy 
volunteers.
In the stable state, there was a negative correlation of 
PGE2 and LTB4 with % predicted forced expiratory volume 
in 1 s and a positive correlation with antibiotic courses.
LXA4 improved blood and airway neutrophil phagocytosis 
and bacterial killing in patients with bronchiectasis. 
Additionally LXA4 reduced neutrophil activation and 
degranulation.
Conclusion There is a dysregulation of lipid mediators 
in bronchiectasis with excess proinflammatory 
lipids. LXA4 improves the function of reprogrammed 
neutrophils. The therapeutic efficacy of LXA4 in 
bronchiectasis warrants further studies.
INTRODUCTION
Excessive inflammation is widely accepted to be 
a unifying component in many chronic diseases, 
including bronchiectasis, vascular diseases, meta-
bolic syndrome and neurological diseases, and thus 
is a public health concern. Understanding endog-
enous control points within the inflammatory 
response could potentially provide us with new 
perspectives on disease pathogenesis and treatment 
approaches. Break in the barrier, trauma and micro-
bial invasion encourage the host to clear microbial 
pathogens, remodel and regenerate tissue. The acute 
inflammatory response is protective and usually 
self- limiting. Oxidative lipid products including, 
notably, the products of unsaturated lipids are 
increasingly being recognised as important contrib-
utors to chronic inflammatory diseases.1 2 Eicosa-
noids3 4 produced from the n- 6 polyunsaturated 
fatty acid, arachidonic acid (20:4), as well as many 
cytokines and chemokines,5 6 have crucial roles in 
the initial response. Interactions among prostaglan-
dins, leukotrienes and proinflammatory cytokines 
amplify inflammation, the signs and effects of which 
can be reduced by pharmacological inhibition and 
receptor antagonists.3–5 However, given that exces-
sive inflammation contributes to several widely 
occurring diseases, improvements are required in 
treatment and in our understanding of the mech-
anisms involved. Eicosanoids also include lipoxins 
that possess potent anti- inflammatory properties.7 
Further, n- 3 fatty acids (eicosapentaenoic acid 20:5, 
and docosahexaenoic acid, 22:6) are precursors 
for proresolving mediators such as resolvins and 
maresins that limit the duration and magnitude of 
inflammatory responses.8 Recent advances have 
facilitated more detailed profiling of lipid media-
tors in serum and at the sites of inflammation.9–11 
Characterisation of these lipids could thereby lead 
Key messages
What is the key question?
 ► Is there a dysregulation of lipids in 
bronchiectasis that leads to unremitting and 
chronic inflammation?
What is the bottom line?
 ► Ex vivo, lipoxin A4 can improve the function of 
reprogrammed blood and airway neutrophils in 
bronchiectasis.
Why read on?
 ► This is the first study assessing the role of 
lipids in bronchiectasis in depth. Here we 
have demonstrated that dysregulation of 
the proinflammatory and anti- inflammatory 
lipids in bronchiectasis contribute to failure of 
resolution of inflammation. Targeting the lipid 
pathways to initiate the resolution process in 
bronchiectasis may lead to development of 
novel non- antibiotic therapy in the stable state.
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to the development of novel anti- inflammatory therapies for 
chronic inflammatory conditions.
Bronchiectasis is characterised by recurrent cough, daily 
sputum production and recurrent chest infections. There is exces-
sive neutrophilic inflammation, but the driver for this unremit-
ting inflammation is not known. We hypothesise that there is a 
failure of resolution of inflammation in bronchiectasis. Recently, 
we have been investigating the lipid pathway to establish if there 
is a dysregulation of the lipids in bronchiectasis contributing to 
the chronic inflammation. While this could be contributing to 
the persistent chronic inflammatory state in bronchiectasis, there 
is currently no data in the literature to indicate the interplay of 
lipid mediators in bronchiectasis.
The aim of our study was to characterise the lipids obtained 
from blood and airway samples in patients with bronchiectasis 
in the stable state and to assess the efficacy of lipoxin A4 (LXA4) 
on neutrophil function.
METHODS
Six healthy volunteers (partners of the patients recruited in the 
study with no background medical conditions and not currently 
on medication), 10 patients with mild bronchiectasis, 15 with 
moderate and 9 with severe bronchiectasis were recruited. All 
participants had 60 mL of blood taken and underwent a bron-
choscopy. Two segments of the lungs were washed out in patients 
with bronchiectasis, an area affected by bronchiectasis and an 
area unaffected by bronchiectasis, predetermined by CT scan of 
chest. This led to patients acting as their own internal control. 
Lipidomics was done on blood and bronchoalveolar samples 
were obtained.
Bronchiectasis severity
The severity of bronchiectasis was calculated using the Bronchi-
ectasis Severity Index (BSI).12 The BSI is a risk stratification tool 
for morbidity and mortality in bronchiectasis. The minimum 
score is 0 and the maximum score is 26. A score between 0 and 
4 indicates mild disease; 5–8 indicates moderate disease; and a 
score of ≥9 indicate severe disease. The BSI was calculated in all 
patients with bronchiectasis taking part in the study.
Inclusion criteria
Inclusion criteria include idiopathic or postinfective bronchiec-
tasis, age >18 years and no infective exacerbation of bronchi-
ectasis for at least 4 weeks prior to giving serum/bronchoscopy.
Exclusion criteria
Patients on statin, aspirin, inhaled corticosteroids and long- term 
macrolides were excluded.
Bronchoscopy
All participants underwent a bronchoscopy. Participants were 
sedated with midazolam±fentanyl. Bronchoalveolar lavage 
(BAL) and brushings were obtained. For patients with bronchi-
ectasis, BAL was done in an area affected by bronchiectasis and 
in an area unaffected by bronchiectasis as identified on CT scans 
done prior to bronchoscopy.
Liquid chromatography–tandem mass spectrometry (LC-MS/
MS) analysis of eicosanoids
Quantification of eicosanoids and related lipid mediators in 
patient bronchoalveolar lavage fluid (BALF) and serum samples 
was performed using LC- MS/MS13 (see online supplemental file, 
online supplemental figure 1 and online supplemental table T1).
LXA4 detection by ELISA
Serum LXA4 was measured as per manufacturer’s instruction 
(Neogen).
LXA4 was the lipid of choice for all the experiments outlined 
in this article as pilot data (data not shown in this paper) using 
sputum and blood from bronchiectasis exacerbations showed 
that LXA4 was the only lipid that improved after treatment with 
antibiotics.
Isolation of blood and airway neutrophils
Freshly drawn blood was collected into 3.8% sodium citrate, and 
granulocytes were subsequently isolated by dextran sedimenta-
tion and discontinuous Percoll gradient.14 Sputum and BAL were 
washed and treated with sputolysin, and airway neutrophils were 
isolated. Anti- CD16 antibodies (Abcam) were used to identify 
neutrophils by flow cytometry.
LXA4 function on reprogrammed bronchiectasis neutrophils
We assessed phagocytosis and killing of green fluorescent protein 
(GFP)–Pseudomonas O1 (PAO1), spontaneous neutrophil apop-
tosis, neutrophil activation (CD62L/CD11b expression) and 
neutrophil degranulation (myeloperoxidase release). Further 
information on the specific experiments is provided in the online 
supplemental file.
Statistical analysis
Flow cytometry analysis was performed using FlowJo V.10.0.4 
(Tree Star, Ashland, Oregon, USA). Results are presented as 
mean±SEM. Paired and unpaired t- tests were used to compare 













Age (years) 55 (4.1) 65 (2.2) 64 (2.2) 52 (6.8)
Biological sex (% 
female)
40 60 22 80
Aetiology
  Idiopathic 10 (100%) 12 (80%) 6 (67%)
  Postinfective 3 (20%) 3 (33%)
Total WCC (×109/L) 6 (0.5) 6.3 (0.4) 9.3 (1.1) 5.9 (0.5)
Neutrophils 3.3 (0.3) 4.1 (0.3) 6.6 (1.1) 3.5 (0.3)
Eosinophils 0.2 (0.04) 0.3 (0.07) 0.2 (0.06) 0.2 (0.06)
Monocytes 0.5 (0.03) 0.6 (0.05) 0.7 (1) 0.5 (0.05)
ESR (mm/hour) 6.7 (1.8) 13.2 (2.9) 19.6 (6.8) 4.8 (1)
CRP (mg/L) 2.8 (0.5) 4 (1) 16 (7.4) 3.2 (1.1)
FEV1 % predicted (L) 95 (5.5) 82 (4) 55 (6.5) –
FVC % predicted (L) 111 (6) 97 (4) 84 (6) –
TLCO % predicted (SI) 94% (4.9) 82% (4.2.) 74% (7.8) –
KCO % predicted (SI) 106% (4.5) 97% (3.7) 100% (7.2) –
Chronic colonisation 5 (50%) 12 (86%) 8 (89%) –
Exacerbations in the 
last year
0.4 (0.3) 2.4 (0.5) 4.2 (0.9) –
Hospital admissions 
in the last year
0 0.05 (0.05) 0.7 (0.2) –
Data presented as mean (±SE of mean).
CRP, C reactive protein; ESR, erythrocyte sedimentation rate; FEV1, forced expiratory volume 
in 1 s; FVC, forced vital capacity; KCO, transfer coefficient corrected for alveolar volume; 
TLCO, transfer factor for the lung for carbon monoxide; WCC, white cell count.
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the two groups, where applicable. Data were analysed by one- 
way analysis of variance (ANOVA) with Bonferonni’s multiple 
comparison post hoc test (GraphPad Prism V.6; GraphPad 
Software, La Jolla, California, USA), when three groups were 
involved. A repeated measures ANOVA was used where samples 
from the same participant receive multiple treatments; signifi-
cance was accepted with p values: *p<0.05.
RESULTS
Baseline demographics of the participants are shown in table 1.
Serum lipidomics
LC- MS/MS was done on all serum samples obtained, where 
available. Only data that passed quality control were used, and 
thus we have a smaller sample size. The demographics are shown 
in online supplemental table 1. Samples were divided into mild9 
and moderate–severe15 bronchiectasis groups (moderate and 
severe groups were combined as lipids were not detected in all 
samples by lipidomics, and hence data were combined to obtain 
meaningful interpretation. Baseline demographics of mild9 and 
moderate–severe15 groups are provided in online supplemental 
table T2.
Figure 1 Significantly higher levels of PGE2, 15- HETE and LTB4 detected in patients with moderate–severe disease compared with healthy 
volunteers; p=0.03, p=0.03 and p=0.02, respectively. higher levels of 5- HETE and 9- HODE detected in patients with more moderate–severe disease 
compared with healthy volunteers, but not statistically significant. Lipidomics were obtained by mass spectrometry and liquid chromatography. Pooled 
data presented as mean±SEM. One- way analysis of variance used for comparisons. Healthy=6 volunteers, mild=9 patients, moderate–severe=15 
patients. 5- HETE, 5- hydroxyeicosatetranoic acid; 15- HETE, 15- hydroxyeicosatetranoic acid; 9- HODE, 9- hydroxyoctadecadienoic acid; LTB4, leukotriene 
B4; PGE2, prostaglandin E2.
Figure 2 Significantly lower level of LXA4 is severe bronchiectasis. 
Healthy, n=6; mild, n=10; moderate, n=15; severe, n=9. Pooled data 
represented as mean±SEM. LXA4, lipoxin A4.
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The main lipids assessed were LXA4, resolvins, maresins, pros-
taglandin E2 (PGE2), 5- hydroxyeicosatetranoic acid (5- HETE), 
15- hydroxyeicosatetranoic acid (15- HETE), leukotriene B4 
(LTB4) and 9- hydroxyoctadecadienoic acid (9- HODE). 15- HETE 
is a precursor of LXA4 and is a proinflammatory mediator. LTB4 
is a proinflammatory cytokine and 9- HODE is a proinflamma-
tory metabolite produced from arachidonic acid.
There were significantly higher levels of PGE2, 15- HETE and 
LTB4 in patients with moderate–severe bronchiectasis compared 
with healthy controls (p=0.03, p=0.03 and p=0.02, respec-
tively). Although there was a trend towards higher 5- HETE and 
9- HODE levels in moderate–severe bronchiectasis compared 
with healthy volunteers, this failed to reach statistical signifi-
cance (p=0.3 and 0.2, respectively). Although there was a trend 
towards higher PGE2, 15- HETE, LTB4, 5- HETE and 9- HODE 
levels between the mild bronchiectasis and healthy volunteers, 
this was not statistically significant (figure 1). LXA4, resolvins 
and maresins were not detected in any of the samples by LC- MS/
MS.
Blood LXA4 measured by ELISA
LXA4 was detected by ELISA. Using one- way ANOVA, we found 
that there was a significantly lower level of LXA4 in severe bron-
chiectasis, p=0.04 (figure 2), as measured by ELISA.
BALF lipidomics
There were significantly higher levels of PGE2, 5- HETE, 
15- HETE, 9- HODE and LTB4 in patients with moderate–severe 
bronchiectasis compared with healthy volunteers (p<0.0001, 
p=0.004, p=0.005, p=0.04 and p<0.0001, respectively) 
(figure 3). Although there was a trend, there was no statistically 
significant difference in the PGE2, 15- HETE, LTB4, 5- HETE and 
9- HODE levels between mild bronchiectasis and healthy volun-
teers. LXA4, resolvins and maresins were not detected in any of 
the samples by LC- MS/MS. PGE2 was not detectable in BALF 
from healthy individuals.
Correlation of blood PGE2 and LTB4 to markers of disease 
severity
There was a positive correlation of PGE2 with antibiotic courses 
(r=0.78, 95% CI 0.61 to 0.88, p<0.0001) and a negative correla-
tion with % predicted forced expiratory volume in 1 s (FEV1) 
(r=−0.46, 95% CI −0.15 to −0.69, p=0.004). Similarly, there 
was a positive correlation of LTB4 with antibiotic courses (r=0.76, 
95% CI 0.56 to 0.87, p<0.0001) and a negative correlation with 
% predicted FEV1 (r=−0.58, 95% CI −0.3 to −0.76, p=0.0003; 
figure 4). There was no correlation of PGE2 or LTB4 to other param-
eters of the disease severity on the BSI. There was no correlation 
of 15- HETE, 5- HETE and 9- HODE to markers of disease severity.
Figure 3 Significantly higher levels of PGE2, 5- HETE, 15- HETE, 9- HODE and LTB4 detected in patients with moderate–severe disease compared with 
healthy volunteers. Lipidomics obtained by mass spectrometry and liquid chromatography. pooled data presented as mean±SEM. One- way analysis 
of variance used for comparisons. Healthy=6 volunteers, mild= 9 patients, moderate–severe=15 patients. 5- HETE, 5- hydroxyeicosatetranoic acid; 15- 
HETE, 15- hydroxyeicosatetranoic acid; 9- HODE, 9- hydroxyoctadecadienoic acid; LTB4, leukotriene B4; PGE2, prostaglandin E2.
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Effect of biological sex on PGE2
There was biological sex imbalance in our cohort, and to inves-
tigate this further, there was a subanalysis of blood PGE2. The 
blood PGE2 was 1.1 (±0.3) for male healthy volunteers and 
1.3 (±0.5) for female healthy volunteers (p=0.2), 4.2 (±1.4) 
for male mild bronchiectasis and 3.9 (±0.1) for female mild 
bronchiectasis (p=0.8), 2.9 (±0.6) for male moderate–severe 
bronchiectasis, and 4.2 (±0.7) for female moderate–severe bron-
chiectasis (p=0.2). This is a small study and so detailed further 
subanalysis was not carried out.
Effect of LXA4 on blood neutrophil function
As we detected significantly lower levels of LXA4 in blood of 
patients with severe bronchiectasis, we investigated the effect 
of LXA4 on reprogrammed neutrophil function.
15 With the 
complexity of the experiments, the authors studied healthy 
controls and patients with mild and severe bronchiectasis only. 
Blood neutrophils from healthy volunteers (n=6) and patients 
with mild (n=10) and severe bronchiectasis (n=9) were 
pretreated ex vivo with varying concentrations of LXA4 for 30 
min and then coincubated with GFP–PAO1. Phagocytosis of 
bacteria (GFP–PAO1) was assessed after 15 min and killing after 
24 hours. Total phagocytosis was calculated by assessing neutro-
phils positive for GFP. Data were analysed by gating the overall 
phagocytosis first. There was no difference in overall phagocy-
tosis in healthy controls and in patients with mild and severe 
bronchiectasis. Next, we gated the neutrophils that had taken 
up much higher number of bacteria, as indicated by the mean 
fluorescence (fluorescence intensity, FLI). This was done at 50% 
of the total phagocytosis and we called this high MFLI phagocy-
tosis. In healthy controls, mild and severe bronchiectasis, LXA4 
was able to significantly improve phagocytosis (comparing only 
the high MFLI and not total phagocytosis) (figure 5A) and killing 
of GFP–PAO1 in a concentration- dependent manner with statis-
tical significance achieved at 100 nM LXA4 (figure 5B).
Effect of LXA4 on airway neutrophil function
Airway neutrophils were isolated from BALF from patients with 
bronchiectasis (no airway neutrophils could be isolated from 
healthy volunteers), and phagocytosis and killing assays were 
performed using GFP–PAO1.
Neutrophils collected from affected lung segments demon-
strated statistically significant improvement in phagocytosis 
(neutrophil gating done as in previous experiment) and killing 
after treatment with 100 nM LXA4 in mild, moderate and severe 
bronchiectases (figure 6A,B). The neutrophils collected from 
unaffected lung segments displayed significant improvement in 
bacterial killing after treatment with 100 nM LXA4 in patients 
with severe bronchiectasis only (p=0.02).
Effect of LXA4 on stable disease-state peripheral blood 
neutrophil spontaneous apoptosis, surface expression of 
CD11b and CD62L, and myeloperoxidase release
For this experiment, blood neutrophils from healthy volunteers 
and patients with stable- state bronchiectasis with either mild and 
moderate–severe disease were pretreated with LXA4 1, 10 and 
100 nM and assessed for the onset of spontaneous apoptosis. 
LXA4 did not significantly modulate spontaneous apoptosis or 
viability of neutrophils (p=0.4, p=0.5 and p=0.4, respectively), 
in contrast to roscovitine, used as a positive control for apoptosis 
induction (online supplemental figure S2).
To evaluate the effect of LXA4 on fMLF- induced neutro-
phil activation, surface expression of CD11b and CD62L was 
measured. In this experiment, LXA4 treatment induced a small but 
statistically significant reduction in fMLF- induced upregulation 
of CD11b and shedding of CD62L in a concentration- dependent 
Figure 4 Using Pearson two- tailed correlation coefficient, we found that there was a correlation between serum PGE2 and antibiotic courses 
received in the preceding year and % predicted FEV1 (A,B). Also, there was a correlation between serum LTB4 and antibiotic courses received in the 
preceding year and % predicted FEV1 (C,D). FEV1, forced expiratory volume in 1 s; LTB4, leukotriene B4; PGE2, prostaglandin E2.
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manner, in healthy volunteers and in patients with mild and 
moderate–severe bronchiectases (online supplemental figure S3 
and 4).
Additionally, LXA4 reduced neutrophil degranulation and 
release of myeloperoxidase in a concentration- dependent 
manner from neutrophils isolated from healthy volunteers and 
in patients with mild and moderate–severe bronchiectasis (online 
supplemental figure S5).
DISCUSSION
This is the first study characterising the lipid profile in bron-
chiectasis blood and airways in the stable state. We established 
that there is a dysregulation of the lipids in serum and airways 
in the stable state. In serum, there was significantly higher levels 
of the proinflammatory metabolites PGE2, 15- HETE and LTB4 
and significantly lower levels of the anti- inflammatory mediator 
LXA4 in severe disease compared with mild disease and healthy 
volunteers. Although LXA4 was not detectable in serum using 
LC- MS/MS, it was detected by ELISA. This can be explained by 
level of sensitivity of the assays used. Detection limits were in 
nanogram per millilitre by LC- MS and in picogram per millilitre 
by ELISA. In the airways, there were significantly higher levels 
of PGE2, 5- HETE, 15- HETE, 9- HODE and LTB4. There was 
a correlation of PGE2 and LTB4 with antibiotic courses and % 
predicted FEV1. Higher levels of PGE2 and LTB4 were inversely 
related to the % predicted FEV1 and directly related to the 
number of antibiotic courses for bronchiectasis exacerbations.
In the stable state, LXA4 was able to significantly improve 
phagocytosis and killing of GFP Pseudomonas aeruginosa by 
blood and airway neutrophils, in a concentration- dependent 
manner. In addition, the authors demonstrated that LXA4 
reduced fMLF- induced neutrophil activation. However, there 
was no effect of LXA4 on spontaneous neutrophil apoptosis.
To the authors’ best knowledge, prostaglandins have not been 
studied in bronchiectasis. In COPD, PGE2 levels are increased 
in the exhaled breath and are known to correlate with airflow 
obstruction.16 17 Additionally, studies have demonstrated that 
PGE2 is a critical component in amplifying and perpetuating 
senescence and inflammation in COPD fibroblasts.18 PGE2 
enhances LTB4- mediated polymorphonuclear leucocyte extrav-
asation and tissue injury that is blocked by topical adminis-
tration of synthetic LXA4.
19 However, prostaglandins are also 
key in the temporal switch of LTB4 to LXA4—a term coined as 
‘lipid mediator class switching’.20 In the stable state, the authors 
demonstrated that PGE2 and LTB4 were significantly higher and 
LXA4 was significantly lower in blood in severe bronchiectasis. 
Serum PGE2 and LTB4 levels were correlated to airflow obstruc-
tion as measured by FEV1. Higher serum PGE2 and LTB4 levels 
were also correlated to more exacerbations requiring antibiotic 
courses in bronchiectasis, both markers of disease severity in 
bronchiectasis.12 Studies have established that disease severity 
in bronchiectasis predicts mortality, hospital admissions, exacer-
bations, quality of life, respiratory symptoms, exercise capacity 
and lung function decline in bronchiectasis.21 This dysregulation 
between lipid mediators that the authors have shown here would 
thereby lead to more inflammation even in the stable state. 
Although PGE2 levels are known to initiate the class switching 
during resolution of inflammation, this was not demonstrated in 
our study. Almost certainly, the levels of LXA4 detected in bron-
chiectasis serum are unable to counter- regulate the production 
of the proinflammatory LTB4.
Figure 5 (A) There was a concentration- dependent increase in phagocytosis induced by LXA4, in healthy volunteers, mild and severe bronchiectasis. 
One- way ANOVA with a Bonferroni correction for multiple comparisons, with p values representing the comparison of control to 1, 10 and 100 
nM of LXA4. Pooled % neutrophil phagocytosis data, showing means±SEM. (B). There was dose- dependent increase in killing with LXA4 in healthy 
volunteers, mild and severe bronchiectasis. One- way ANOVA with Bonferonni’s correction for multiple comparisons used, with p values representing 
the comparison of control to 1, 10 and 100 nM of LXA4. Pooled % neutrophil killing data showing means±SEM. ANOVA, analysis of variance; LXA4, 
lipoxin A4.
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In addition to PGE2 and LTB4, the other metabolites (5- HETE, 
15- HETE and 9- HODE) detected in our study are also proin-
flammatory mediators, and they remain elevated even in the 
stable state in moderate and severe bronchiectases compared 
with mild disease. LTB4 has been studied in bronchiectasis and is 
known to be one of the major chemotactic factors in the bron-
chial airways in bronchiectasis.22 Additionally, there is evidence 
to suggest that LTB4 is raised during an exacerbation and reduces 
with antibiotic therapy.23 Persistently elevated lipid mediators 
in bronchiectasis, in part, may explain why more patients with 
moderate–severe bronchiectasis have a higher mortality rate 
and more hospital admissions compared with patients with mild 
disease.12
LXA4 was able to improve blood and airway neutrophil 
bacterial phagocytosis and killing, thereby enhancing bacterial 
clearance and potentially having long- term consequences on 
infection, inflammation and resolution. The impact of LXA4 on 
bronchiectasis airway neutrophil function was more pronounced 
when neutrophils were isolated from a disease- affected lung 
region than an unaffected region. The mechanism underpinning 
this observation remains to be determined, but this raises the 
intriguing possibility that regional lung patterning of LXA4 defi-
ciency might exist, with cells collected having had divergent in 
vivo exposure to LXA4 before experimental use.
LXA4 was able to reduce fMLF- induced CD11b upregula-
tion, CD62L shedding and myeloperoxidase release. These 
anti- inflammatory functions of LXA4 have previously been 
demonstrated in the literature.17 However, this is the first time 
that the effects of lipoxins have been demonstrated on a subset 
of reprogrammed neutrophils from patients with bronchiectasis.
Biological sex may have an effect on the dynamics of the 
lipids in bronchiectatic airways. We did not identify differences 
with blood PGE2, but as this was a small study, further detailed 
subanalysis was not carried out. Further studies would be needed 
to explore this.
The authors have shown that serum neutrophils are repro-
grammed in bronchiectasis, leading to persistent and unresolving 
inflammation.15 This study now demonstrates that there is a 
dysregulation of the lipid mediators and failure of class switching 
during inflammation in bronchiectasis, despite adequate levels 
of PGE2. Whether there is a role of cyclo- oxygenase inhibitors 
in bronchiectasis to block the production of PGE2 needs to be 
explored further. Certainly, with the emergence of antibiotic 
resistance, the role of novel specialised proresolving lipid medi-
ators is promising, especially in bronchiectasis, where recurrent 
exacerbations requiring antibiotic therapy is one of the cardinal 
features of the disease.
Limitations of the study
There are a couple of limitations in this study: first, that this is a 
small study, and second, this study did not assess the role LXA4 
on bronchiectasis neutrophils during exacerbations.
CONCLUSION
There is a dysregulation of lipid mediators in bronchiectasis in the 
stable state with excess proinflammatory lipids. LXA4 improves 
the function of reprogrammed neutrophils. The therapeutic effi-
cacy of LXA4 in bronchiectasis warrants further studies.
Figure 6 (A) Bacterial phagocytosis and (B) killing. LXA4 significantly increased phagocytosis and killing of PAO1 by airway neutrophils isolated 
from the lung segments affected by Bx in mild, moderate and severe diseases. In unaffected segments, LXA4 only had an improvement in bacterial 
killing in patients with severe Bx only. Pooled data presented as mean±SEM. Paired t- tests used for all comparisons. Bx, bronchiectasis; LXA4, lipoxin 
A4; PAO1, Pseudomonas O1.
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6 keto PGF1a 369.2 163.2 9 HETE 319.2 151.3 
20 OH LTB4 351.2 195.2 11,12 dHET 337.2 167.2 
20 COOH LTB4 365.2 195.1 14,15 dHET d11 348.3 207.2 
11 dehydro TxB2 367.2 161.2 15 HEPE 317.2 219.2 
8IsoPGF2a 353.2 193.2 8,9 dHET 337.2 127.2 
TxB2 369.2 169.1 12 HEPE 317.2 179.2 
iPF2a VI 353.2 115.2 5 HEPE 317.2 115.2 
11beta PGF2a 353.2 193.1 5,6 dHET 337.2 145.1 
PGE2 351.2 271.2 13 HODE 295.3 195.2 
dihydro PGE2 351.2 235.0 20 HETE 319.2 245.3 
PGE2 d4 355.2 193.2 7 HDHA 343.2 141.2 
PGD2 351.2 233.1 9 HODE 295.3 171.2 
dihydro PGD2 351.2 175.2 15 OxoETE 317.2 113.3 
PGF2a 353.3 193.2 15 HETE 319.2 219.2 
RvD2 375.2 175.1 8 HETE 319.2 155.2 
LXA4 351.2 115.3 11 HETE 319.2 167.2 
RvD1 375.2 215.2 12 HETE 319.3 179.2 
LTD4 495.3 177.0 15 HETE d8 327.3 226.1 
5,6 EET 319.2 191.3 17 HDHA 343.3 281.3 
Maresin 1 359.2 177.2 14 HDHA 343.3 205.2 
LTB4 335.2 195.2 9,10 EpOME 295.2 171.2 
LTB4 d4 339.2 197.2 5 OxoETE 317.2 203.3 
10,17 diHDHA 359.2 153.2 5 HETE 319.3 115.2 
LTE4 438.2 333.3 14,15 EET d11 330.3 175.2 
LTE4 d5 443.3 338.2 11,12 EET 319.2 167.2 
15deoxy D 12,14 
PGJ2 
315.2 271.2 8,9 EET 319.3 155.2 
14,15 dHET 337.2 207.2 14,15 EET 319.3 175.2 
9,10 diHOME 313.2 201.2    
Table T1: Compounds monitored by liquid chromatography mass spectrometry. 
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Effect of LXA4 on stable disease state peripheral blood neutrophil spontaneous 
apoptosis, surface expression of CD11b and CD62L and myeloperoxidase release 
 
For this experiment, blood neutrophils from healthy volunteers, and stable state 
bronchiectasis patients with either mild or severe disease were pre-treated with LXA4 
1nM, 10nM, and 100nM and assessed for the onset of spontaneous apoptosis. LXA4 
did not significantly modulate spontaneous apoptosis or viability of neutrophils 
(p=0.4, p=0.5 and p=0.4 respectively), in contrast to Roscovitine, used a positive 
control for apoptosis induction (figure S1).  
 
Figure S2. Blood neutrophils from (a) healthy volunteer, (b) mild and (c) severe 
bronchiectasis patients were cultured for 20 hours and cell viability, apoptosis and 
necrosis were assessed by flow cytometry. There was no effect of LXA4, even at a 
maximum dose of 100nM, on spontaneous apoptosis at 20 hours. Pooled data 
presented as mean +/- SEM; n=6 per group. Analysis by two way ANOVA. 
Roscovitine is a CDK-inhibitor that promotes apoptosis and was used as a positive 
control (5).  
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Effect of LXA4 on fMLF induced upregulation of CD11b 
 
Figure S3. There was a concentration-dependent reduction of fMLF-induced 
activation (30 minutes) and CD11b expression by LXA4; p=0.005 healthy volunteers; 
p=0.008 mild bronchiectasis; p=0.01 severe bronchiectasis. Pooled data presented as 
mean ± SEM; n=6 per group. Analysis by one-way ANOVA. BX= bronchiectasis; 
NC= negative control; fMLF= n- formyl-methyl- leucyl- phenylalanine; LX= Lipoxin 
A4. 
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Effect of LXA4 on fMLF induced shedding of CD62L 
 
Figure S4. There was a concentration-dependent reduction of fMLF-induced 
activation and CD62L shedding by LXA4; p=0.01 healthy volunteers; p=0.03 mild 
bronchiectasis; p=0.04 severe bronchiectasis. Pooled data presented as mean ± SEM; 
n=6 per group. Analysis was done by one-way ANOVA. BX= bronchiectasis; NC= 
negative control; fMLF= n- formyl-methyl- leucyl- phenylalanine; LX= Lipoxin A4. 
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Figure S5. There was a concentration-dependent  reduction of fMLF (30 minutes) and 
cytochalasin B (10 minutes) induced activation and release of MPO by LXA4, (a) 
p=0.02 healthy volunteers; (b) p=0.04 mild bronchiectasis; (c) p=0.02 severe 
bronchiectasis (In severe bronchiectasis, LX 100nM on its own seems to increase 
MPO generation - this is due to one experimental data set, which skewed the overall 
result). Pooled data presented as mean ± SEM. Analysis done by one way ANOVA. 
Cyt= Cytochalasin B; F=fMLF= n-formyl- methyl-leucyl-phenylalanine; NC= 
negative control; LX= LXA4. 
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Hospital admissions in 
the last year 
0 0.3 
(0.1) 
Table T2. Baseline demographics of the sub study population. Data presented as mean (± 
standard error of mean). 
CRP= c reactive protein; ESR= erythrocyte sedimentation rate; FEV1= forced expiratory 
volume in 1sec; FVC= forced vital capacity; KCO= transfer coefficient corrected for alveolar 
volume; TLCO= transfer factor for the lung for carbon monoxide; WCC= white cell count. 
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